Antigens, CD86

• 

  Subject Areas on Research

  • Activation of human B cells by phosphorothioate oligodeoxynucleotides. 
  • Adjuvanticity and protective immunity of Plasmodium yoelii nigeriensis blood-stage soluble antigens encapsulated in fusogenic liposome. 
  • CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. 
  • CD7 and CD28 are required for murine CD4+CD25+ regulatory T cell homeostasis and prevention of thyroiditis. 
  • CD86 (B7-2) can function to drive MHC-restricted antigen-specific CTL responses in vivo. 
  • Cellular FLIP Inhibits Myeloid Cell Activation by Suppressing Selective Innate Signaling. 
  • Cellular interaction in germinal centers. Roles of CD40 ligand and B7-2 in established germinal centers. 
  • Characterization of dendritic-like cells derived from t(9;22) acute lymphoblastic leukemia blasts. 
  • Combination induction therapy with monoclonal antibodies specific for CD80, CD86, and CD154 in nonhuman primate renal transplantation. 
  • Comparison of thymocyte development and cytokine production in CD7-deficient, CD28-deficient and CD7/CD28 double-deficient mice. 
  • Costimulatory molecules are active in the human xenoreactive T-cell response but not in natural killer-mediated cytotoxicity. 
  • Early B-cell activation after West Nile virus infection requires alpha/beta interferon but not antigen receptor signaling. 
  • Engineering DNA vaccines via co-delivery of co-stimulatory molecule genes. 
  • Evaluation of CD86/CD28 and CD40/CD154 pathways in regulating monocyte-derived CD80 expression during their interaction with allogeneic endothelium. 
  • GPI-defective monocytes from paroxysmal nocturnal hemoglobinuria patients show impaired in vitro dendritic cell differentiation. 
  • GRP94 (gp96) and GRP94 N-terminal geldanamycin binding domain elicit tissue nonrestricted tumor suppression. 
  • Identifying regulatory B cells (B10 cells) that produce IL-10 in mice. 
  • Immunomodulator effect of picroliv and its potential in treatment against resistant Plasmodium yoelii (MDR) infection in mice. 
  • Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. 
  • Intracellular adhesion molecule-1 modulates beta-chemokines and directly costimulates T cells in vivo. 
  • Lymphadenopathy, splenomegaly, and altered immunoglobulin production in BCL3 transgenic mice. 
  • Modification of host dendritic cells by microchimerism-derived extracellular vesicles generates split tolerance. 
  • Release of endogenous danger signals from HIFU-treated tumor cells and their stimulatory effects on APCs. 
  • Repression of B7.2 on self-reactive B cells is essential to prevent proliferation and allow Fas-mediated deletion by CD4(+) T cells. 
  • Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity. 
  • T cell-mediated elimination of B7.2 transgenic B cells. 
  • The B7-2 (B70) costimulatory molecule expressed by monocytes and activated B lymphocytes is the CD86 differentiation antigen. 
  • The modulation of dendritic cell integrin binding and activation by RGD-peptide density gradient substrates. 
  • The use of self-adjuvanting nanofiber vaccines to elicit high-affinity B cell responses to peptide antigens without inflammation. 
  • Transient CD86 expression on hepatitis C virus-specific CD8+ T cells in acute infection is linked to sufficient IL-2 signaling.